Mode
Text Size
Log in / Sign up
N/A Completed N=15,268

Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen

Hypertension · Metabolic Syndrome X
Source: ClinicalTrials.gov NCT00613314 ↗
Enrolled (actual)
15,268
Serious AEs
0.0%
Results posted
Mar 2010
Primary outcomePrimary: Response Rate at the End of 30 Day Period — 41.4; 66.3; 31.2 Percentage of patients

Summary

To determine the efficacy and safety of telmisartan-based treatment among patients with metabolic syndrome in actual setting in Philippines.

Outcome Measures

OutcomeResultp-value
PRIMARY
Response Rate at the End of 30 Day Period
41.4; 66.3; 31.2 —
PRIMARY
Response Rate at the End of 60 Day Period
75.5; 88.1; 69.1 —
PRIMARY
Change in Systolic Blood Pressure (SBP) From Baseline
30.2 —
PRIMARY
Change in Diastolic Blood Pressure (DBP) From Baseline
15.9 —
SECONDARY
Percentage of Patients With Presence of Metabolic Risk Factor
20.0 —

Eligibility Criteria

Inclusion Criteria

  • Age > 45 years
  • Increased waist circumference (>88.9cm [>35in] men, >78.7cm [>31in] for women)
  • Elevated triglycerides (>150mg/dl)
  • Low HDL cholesterol ( 130/>85mmHG)
  • Impaired fasting glucose (>110mg/dl) (8)
  • Hypertensive patient assessed to benefit from telmisartan based treatment

Exclusion Criteria

  • Hypersensitivity to telmisartan, hydrochlorothiazide (HCTZ) and its excipients
  • <3 months myocardial infarction (MI), stroke or severe heart failure
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00613314). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search